Short answer
Vera Therapeutics, Inc. (VERA) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026, released August 10, 2026.
Vera Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026, released August 10, 2026
- Corporate updates included alongside earnings release
- Detailed financial results and updates furnished in Exhibit 99.1
- Disclosure furnished under Item 2.02, limiting Section 18 liability and automatic incorporation into other filings
Item EX-99.1 · Exhibit EX-99.1
- FDA accelerated approval and U.S. launch make TRUTAKNA Vera’s first commercial product and establish a potential IgAN growth platform
- ORIGIN 3 final efficacy analysis expected Q3 2026, with supplemental BLA submission expected Q4 2026 and potential full approval in 2027
- ORIGIN trial showed 42% proteinuria reduction versus placebo, supporting launch differentiation but leaving long-term kidney benefit unconfirmed
- Q2 net loss widened to $109.5M from $76.5M, while six-month operating cash use reached $206.8M
- Cash, equivalents and marketable securities totaled $499.2M, plus up to $425M available under debt facility subject to conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vera Therapeutics, Inc. 8-K filings
Get the next VERA 8-K as it lands
Follow VERA for push alerts, or ask the research agent what this filing means.